The Toronto SPV bioprosthesis: one-year results in 100 patients.
BACKGROUND
We studied the long-term results of heart valve replacement with the Toronto SPV bioprosthesis.


METHODS
From March 1993 until July 1994 the Toronto stentless bioprosthesis was implanted in 100 selected patients with a mean age of 70.7 years. The predominant aortic valve lesion was stenosis in 94 and insufficiency in 6 cases. Eighty-eight patients received a valve 25 mm in diameter or larger. Additional coronary artery bypass grafting was performed in 37 cases. Hospital mortality was 4%. Seventy-four patients were seen at 6 months and 38 patients at 1 year follow-up.


RESULTS
Structural deterioration, thromboembolism or hemorrhage were not encountered. Nonstructural dysfunction lead to reoperation in 1 patient. Another patient presented with endocarditis at 1 year postoperatively. There were no other valve-related complications. Echocardiographic mean pressure gradients ranged from 7.7 to 11.1 mm Hg postoperatively. There was a significant decrease in pressure gradients at 6 months of follow-up. Minimal aortic valve incompetence was seen in 3 patients.


CONCLUSIONS
The Toronto stentless bioprosthesis has superior hemodynamics and is an excellent alternative to conventional stented bioprostheses. Long-term evaluation has to prove whether this promising new valve can live up to its expectations.
Mohr
F W
FW
Department of Thoracic and Cardiovascular Surgery, Georg-August-University Göttingen, Germany.
Walther
T
T
Baryalei
M
M
Falk
V
V
Autschbach
R
R
Scheidt
A
A
Dalichau
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery; D001022:Aortic Valve Insufficiency / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D001705:Bioprosthesis; D005069:Evaluation Studies as Topic; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies